

valine-, carbobenzyloxy-leucine-valine-, carbobenzyloxy-phenylalanine-valine-, carbobenzyloxy-serine-valine-, carbobenzyloxy-threonine-valine- , carbobenzyloxy-alanine-asparagine- and carbobenzyloxy-valine-valine-; and

R_2 is a radical selected from the group consisting of -(H)₂, and -H(t-Butyl).

Remarks

Claims 11, 16, and 17 were objected to as depending upon rejected claims. In conformance with Examiner's objections, claims 11, 16, and 17 have been amended so that each is now an independent claim.

Examiner objected that claim 3 was poorly legible. Per Examiner's request, Claim 3 (once amended) has been reproduced here without further amendment.

Rejection under 35 U.S.C. § 102(b):

Claim 1 is rejected as anticipated by Tam. Applicant traverses this rejection. However, Applicant has canceled claim 1 without prejudice and reserves the right to pursue this claim in a continuation application.

Rejection under 35 U.S.C. § 103(a):

Claims 10 and 12-15 are rejected as obvious over Wo. Applicant traverses this rejection. However, Applicant has canceled claims 10 and 12-15 without prejudice and reserves the right to pursue these claims in a continuation application.

Summary:

Applicant has cancelled all rejected claims (claims 1, 10, and 12-15). Furthermore, Applicant has amended all claims to which Examiner has objected (11, 16,m and 17), so as to bring these claims into conformance with Examiner's objections.

Applicant requests that the above amendments after final be entered and that a Notice of Allowance be provided with respect to claims 3, 6-9, 11, and 16-22.

Respectfully submitted,



Donald G. Lewis
Reg. No. 28,636
The Scripps Research Institute
10550 N. Torrey Pines Road TPC-8
San Diego, CA 92037
July 3, 2003
(858) 784-2937